#USA #Leesburg #biorepository #Creapharm Bioservices #Resonant Clinical Solutions

Resonant Clinical Solutions Enhances Its Offerings with Acquisition of Creapharm Bioservices

In an impressive development for the life sciences sector, Resonant Clinical Solutions announced its acquisition of Creapharm Bioservices, a notable player in the biobanking and cryogenic storage landscape. This acquisition highlights Resonant's commitment to expanding its capabilities, particularly in support of complex clinical trials involving advanced therapies such as cell and gene therapies.

The deal, which was officially unveiled on September 3, 2026, is a significant step for Resonant, headquartered in Leesburg, Virginia. With this acquisition, the company aims to enhance its Biorepository services across Europe. By bringing Creapharm into its fold, Resonant is poised to meet the growing demands of life sciences organizations that are increasingly relying on specialized partners to manage the complexities of clinical trial pipelines.

Creapharm, based in Bailly-Romainvilliers, France, is recognized for its specialized services in biobanking and cryogenic storage. These services include the capability to store biotherapeutics, Advanced Therapy Medicinal Products (ATMPs), and other biological samples under stringent conditions, with temperatures ranging from -196°C to higher levels, achieved through state-of-the-art vapor-phase nitrogen storage and mechanical freezer solutions. The facility’s adherence to Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) ensures that the samples are maintained under the highest standards of quality control.

Addressing the Growing Need for Specialized Solutions

A recent report by IQVIA highlighted a significant shift in clinical trial landscapes, noting that non-small-molecule assets—including advanced modalities like gene therapies—composed 46% of Phase I-III clinical trial starts in 2024, marking an increase from 38% over the preceding five years. This trend underscores the necessity for companies to have access to partners like Resonant that possess the specialized infrastructure and expertise needed to navigate the evolving landscape of clinical programs.

Christophe Berthoux, CEO of Resonant Clinical Solutions, expressed excitement about the acquisition, stating, “As life sciences companies increasingly need partners with specialized expertise, Creapharm Bioservices enhances our capabilities to support customers developing complex and sensitive therapies.” This statement reflects Resonant's strategic vision to bolster its support for the clinical trial lifecycle, ensuring that all aspects—ranging from sample storage to logistics—are covered efficiently on a global scale.

The integration of Creapharm into Resonant’s Biorepository segment also adds substantial value through enhanced cryogenic storage capabilities, chain-of-custody management, and an established infrastructure compliant with essential regulatory frameworks. Additionally, Creapharm's experience in handling Class 1 and Class 2 genetically modified organisms (GMOs) further strengthens Resonant's position in the market.

Looking Forward

The implications of this acquisition are profound, not only for Resonant but for the life sciences sector as a whole. With more than 850 employees and experience supporting over 2,500 clinical trials, Resonant's acquisition of Creapharm Bioservices is expected to foster innovation and efficiency in clinical research. This positioning allows Resonant to leverage a more extensive network of customer relationships and research resources across Europe, a region that is rapidly becoming a hub for advanced therapeutic research and development.

As the life sciences sector continues to evolve, partnerships like the one between Resonant Clinical Solutions and Creapharm Bioservices demonstrate the importance of collaboration in meeting the demands of increasingly complex clinical trials. Together, they’ll push the boundaries of what is possible, ensuring that vital therapies reach patients in need while maintaining the integrity and quality of the therapeutic materials involved.

For further information on this acquisition and Resonant Clinical Solutions' offerings, visit resonantclinical.com.